Editas Medicine (EDIT) Expected to Announce Quarterly Earnings on Wednesday

Editas Medicine (NASDAQ:EDIT) is expected to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect Editas Medicine to post earnings of ($0.43) per share and revenue of $37.17 million for the quarter.

Editas Medicine Price Performance

Editas Medicine stock opened at $1.92 on Monday. The stock has a market capitalization of $158.08 million, a P/E ratio of -0.75 and a beta of 1.94. Editas Medicine has a 12-month low of $1.12 and a 12-month high of $11.58. The firm’s 50-day moving average is $1.37 and its two-hundred day moving average is $2.56.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Stifel Nicolaus lowered shares of Editas Medicine from a “buy” rating to a “hold” rating and decreased their target price for the stock from $11.00 to $3.00 in a research report on Friday, December 13th. Wells Fargo & Company downgraded Editas Medicine from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $7.00 to $4.00 in a research report on Wednesday, December 11th. Barclays dropped their target price on Editas Medicine from $5.00 to $3.00 and set an “equal weight” rating for the company in a research note on Friday, December 13th. Robert W. Baird decreased their price target on Editas Medicine from $10.00 to $8.00 and set an “outperform” rating on the stock in a research note on Friday, December 13th. Finally, Evercore ISI lowered their price target on Editas Medicine from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Monday, December 16th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Editas Medicine presently has an average rating of “Hold” and a consensus target price of $7.00.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.